BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2025 and highlighted recent developments.
“During our third quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We expect to initiate our Phase 2b clinical study of IKT-001, our prodrug of imatinib mesylate, in PAH during the fourth quarter of 2025.”
Recent Developments:
Advancement of IKT-001 as a therapy in PAH:
The proposed Phase 2b IMPROVE-PAH trial is a multi-center, randomized, double-blind, placebo-controlled study of approximately 150 PAH participants. Participants under IMPROVE-PAH will be randomized 1:1:1 to receive 300 mg IKT-001, 500 mg IKT-001, or placebo once daily for 26 weeks, in addition to stable background PAH therapy. The Company’s bioequivalence studies previously confirmed that 500 mg of IKT-001 has comparable exposure in humans to 383 mg of imatinib. The primary efficacy endpoint is change in pulmonary vascular resistance at Week 26. Secondary endpoints include 6-minute walk distance, World Health Organization functional class, and pharmacokinetics. The study protocol also includes an interim safety review for study continuance by the Data Safety Monitoring Board with at least 50 patients at 12-weeks of follow-up.
The Company has been actively working with potential sites and presently expects to initiate IMPROVE-PAH in the fourth quarter of 2025.
Appointed veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer.
The Company also expects to present at the Jefferies Global Healthcare Conference in London on Monday, November 17th, 2025.
Financial Results
Cash Position: As of September 30, 2025, cash, cash equivalents and marketable securities were $77.3 million as compared to $97.5 million as of December 31, 2024.
Net Loss: Net loss for the quarter ended September 30, 2025, was $11.9 million, or $0.13 per share, compared to a net loss of $5.8 million, or $0.65 per share in the quarter ended September 30, 2024. Net loss for the nine months ended September 30, 2025, was $35.5 million, or $0.40 per share, compared to a net loss of $15.4 million, or $2.03 per share, for the nine months ended September 30, 2024.
R&D Expenses: Research and development expenses were $7.6 million for the quarter ended September 30, 2025, compared to $4.2 million for the quarter ended September 30, 2024. Research and development expenses were $23.4 million for the nine months ended September 30, 2025, which includes a non-cash write-off of in-process research and development of $7.4 million and $1.8 million of stock-based compensation expense, both associated with the Company’s acquisition of CorHepta in February 2025, compared to $10.0 million for the nine months ended September 30, 2024.
SG&A Expenses: Selling, general and administrative expenses for the quarter ended September 30, 2025 were $5.6 million, compared to $1.6 million for the quarter ended September 30, 2024. Selling, general and administrative expenses for the nine months ended September 30, 2025 were $16.8 million, which includes $1.0 million of severance expenses resulting from the transition of senior executives in the Company during the year, compared to $5.6 million for the nine months ended September 30, 2024.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, PAH, that arise from aberrant signaling through the Abelson Tyrosine Kinase, and type III receptor tyrosine kinases including platelet derived growth factor receptors and c-KIT. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate, for PAH which is an orphan indication. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans.
Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the potential effects of IKT-001, the initiation of the Company’s Phase 2b trial of IKT-001 in PAH, including timing related thereto, and the Company’s future activities, or future events or conditions. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to commence and execute a Phase 2b trial to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
---tables to follow---
Inhibikase Therapeutics, Inc. | ||||||||
September 30, | December 31, | |||||||
(unaudited) | (Note 3) | |||||||
Assets | | |||||||
Current assets: | | |||||||
Cash and cash equivalents | $ | 38,269,706 | $ | 56,490,579 | ||||
Marketable securities | 39,052,511 | 41,052,949 | ||||||
Prepaid research and development | 210,566 | 81,308 | ||||||
Deferred offering costs | 385,062 | — | ||||||
Prepaid expenses and other current assets | 618,783 | 826,473 | ||||||
Total current assets | 78,536,628 | 98,451,309 | ||||||
Equipment and improvements, net | — | 47,100 | ||||||
Right-of-use asset | — | 101,437 | ||||||
Prepaid research and development, noncurrent | 1,000,000 | — | ||||||
Other assets | 57,913 | — | ||||||
Total assets | $ | 79,594,541 | $ | 98,599,846 | ||||
Liabilities and stockholders’ equity | | |||||||
Current liabilities: | | |||||||
Accounts payable | $ | 620,528 | $ | 943,019 | ||||
Lease obligation, current | — | 110,517 | ||||||
Accrued expenses and other current liabilities | 3,656,383 | 2,680,030 | ||||||
Contingent consideration liability | 2,419,332 | — | ||||||
Total current liabilities | 6,696,243 | 3,733,566 | ||||||
Total liabilities | 6,696,243 | 3,733,566 | ||||||
Commitments and contingencies (see Note 16) | | |||||||
Stockholders’ equity: | | | ||||||
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2025 and December 31, 2024 | — | — | ||||||
Common stock, $0.001 par value; 500,000,000 and 100,000,000 shares authorized; 74,807,911 and 69,362,439 shares issued and outstanding (including 4,149,252 and 0 contingently issuable shares – see Note 10) at September 30, 2025 and December 31, 2024, respectively | 74,808 | 69,362 | ||||||
Additional paid-in capital | 202,772,828 | 189,254,777 | ||||||
Accumulated other comprehensive loss | (4,189 | ) | (37,248 | ) | ||||
Accumulated deficit | (129,945,149 | ) | (94,420,611 | ) | ||||
Total stockholders' equity | 72,898,298 | 94,866,280 | ||||||
Total liabilities and stockholders’ equity | $ | 79,594,541 | $ | 98,599,846 | ||||
Inhibikase Therapeutics, Inc. | ||||||||||||||||
Three Months Ended September 30, | Nine months ended September 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Costs and expenses: | ||||||||||||||||
Research and development | $ | 7,649,697 | $ | 4,189,873 | $ | 23,434,243 | $ | 10,016,982 | ||||||||
Selling, general and administrative | 5,611,503 | 1,637,603 | 16,780,525 | 5,643,386 | ||||||||||||
Change in fair value contingent consideration | (492,827 | ) | — | (2,016,111 | ) | — | ||||||||||
Total costs and expenses | 12,768,373 | 5,827,476 | 38,198,657 | 15,660,368 | ||||||||||||
Loss from operations | (12,768,373 | ) | (5,827,476 | ) | (38,198,657 | ) | (15,660,368 | ) | ||||||||
Interest income | 838,093 | 49,410 | 2,674,119 | 273,059 | ||||||||||||
Net loss | (11,930,280 | ) | (5,778,066 | ) | (35,524,538 | ) | (15,387,309 | ) | ||||||||
Other comprehensive income (loss), net of tax | ||||||||||||||||
Unrealized gain (loss) on marketable securities | (1,245 | ) | 2,778 | 33,059 | 877 | |||||||||||
Comprehensive loss | $ | (11,931,525 | ) | $ | (5,775,288 | ) | $ | (35,491,479 | ) | $ | (15,386,432 | ) | ||||
Net loss per share – basic and diluted | $ | (0.13 | ) | $ | (0.65 | ) | $ | (0.40 | ) | $ | (2.03 | ) | ||||
Weighted-average number of shares – basic and diluted | 90,050,973 | 8,882,570 | 89,867,805 | 7,592,103 | ||||||||||||
Inhibikase Therapeutics, Inc. | ||||||||
Nine months ended September 30, | ||||||||
2025 | 2024 | |||||||
Cash flows from operating activities | ||||||||
Net loss | $ | (35,524,538 | ) | $ | (15,387,309 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 60,499 | 19,705 | ||||||
Stock-based compensation expense | 10,776,144 | 232,155 | ||||||
Write-off of in-process research and development | 7,357,294 | — | ||||||
Change in fair value of contingent consideration | (2,016,111 | ) | — | |||||
Noncash accretion on marketable securities | (570,503 | ) | — | |||||
Changes in operating assets and liabilities: | ||||||||
Operating lease right-of-use assets | 101,437 | 89,122 | ||||||
Prepaid expenses and other assets | 257,321 | 698 | ||||||
Prepaid research and development | (1,129,258 | ) | 107,592 | |||||
Other assets | (57,913 | ) | — | |||||
Accounts payable | (390,699 | ) | 1,329,135 | |||||
Operating lease liabilities | (110,517 | ) | (95,009 | ) | ||||
Accrued expenses and other current liabilities | 976,353 | (98,581 | ) | |||||
Net cash used in operating activities | (20,270,491 | ) | (13,802,492 | ) | ||||
Cash flows from investing activities | ||||||||
Purchases of equipment and improvements | (13,399 | ) | — | |||||
Purchases of investments – marketable securities | (38,996,000 | ) | (10,343,939 | ) | ||||
Maturities of investments – marketable securities | 41,600,000 | 12,101,463 | ||||||
Acquired in-process research and development | (438,624 | ) | — | |||||
Net cash provided by investing activities | 2,151,977 | 1,757,524 | ||||||
Cash flows from financing activities | ||||||||
Deferred offering costs | (385,062 | ) | — | |||||
Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs | 150 | 3,793,209 | ||||||
Issuance of common stock from exercise of stock options | 282,553 | — | ||||||
Net cash provided by (used in) financing activities | (102,359 | ) | 3,793,209 | |||||
Net decrease in cash and cash equivalents | (18,220,873 | ) | (8,251,759 | ) | ||||
Cash and cash equivalents at beginning of period | 56,490,579 | 9,165,179 | ||||||
Cash and cash equivalents at end of period | $ | 38,269,706 | $ | 913,420 | ||||
Supplemental disclosures of cash flow information | ||||||||
Issuance costs | $ | — | $ | 1,203,350 | ||||
Non cash investing and financing activities | ||||||||
Non-cash financing costs included in accounts payable | $ | — | $ | 553,318 | ||||
CorHepta transaction costs | $ | 175,000 | $ | — | ||||
Contingent consideration | $ | 2,419,332 | $ | — | ||||